Table 2 Prevalence and cumulative incidence at 6 years of allergy related diseases, wheeze and lower respiratory tract infections in the probiotic and placebo groups
Imputed estimates | Observed cases | |||||||
|---|---|---|---|---|---|---|---|---|
Allergy related disease | Probiotic, n=211 | Placebo, n=204 | Odds ratio (95 % CI)a | Probiotic | Placebo | Odds ratio | ||
% (95 % CI) | % (95 % CI) | n/n | % (95 % CI) | n/n | % (95 % CI) | (95 % CI)a | ||
Current disease | ||||||||
Asthma | 2.3 (0.0-4.7) | 0.9 (0.0-2.5) | 1.68 (0.21-13.20) | 3/136 | 2.2 (0.7-6-7) | 1/145 | 0.7 (0.0-4.8) | 3.25 (0.33-31.6) |
Allergic sensitisation | 30.0 (21.2-38.8) | 28.0 (18.8-37.1) | 1.11 (0.62-1.96) | 23/80 | 28.8 (19.7-39.8) | 19/78 | 24.4 (16.0-35.3) | 1.25 (0.62-2.54) |
Cumulative incidence | ||||||||
Atopic dermatitis | 29.3 (21.2-37.4) | 39.1 (30.2-48.0) | 0.64 (0.39-1.07)b | 22/81 | 27.2 (17.3-37.1) | 36/82 | 43.9 (32.9-54.9) | 0.48 (0.25-0.92)c |
ARC | 21.6 (14.6-28.6) | 18.8 (12.0-25.7) | 1.19 (0.66-2.16) | 22/134 | 16.4 (10.1-22.8) | 20/145 | 13.8 (8.1-19.5) | 1.22 (0.64-2.37) |
Wheeze | 39.0 (30.9-47.1) | 45.8 (37.4-54.1) | 0.75 (0.47-1.22) | 46/132 | 34.9 (26.7-43.0) | 55/142 | 38.7 (30.7-46.8) | 0.85 (0.52-1.38) |
LRTI (any) | 30.6 (22.2-39.1) | 36.8 (29.1-44.5) | 0.76 (0.47-1.23) | 33/128 | 25.8 (18.1-33.4) | 40/138 | 29.0 (21.4-36.6) | 0.85 (0.50-1.46) |
Bronchitis | 23.6 (16.3-30.9) | 27.6 (20.2-35.0) | 0.81 (0.48-1.36) | 29/130 | 22.3 (15.1-29.5) | 32/139 | 23.0 (16.0-30.1) | 0.96 (0.54-1.70) |
Pneumonia | 10.2 (4.5-15.9) | 15.4 (9.4-21.4) | 0.61 (0.29-1.32) | 7/129 | 5.4 (1.5-9.4) | 17/141 | 12.1 (6.6-17.5) | 0.42 (0.17-1.04)d |